SCHEMBL1689174

SCHEMBL1689174

NC(=O)C(C(=O)Nc1ccccc1)c1ccc(C(=O)Nc2cc(-c3ccccc3)ccc2N)cc1

nearest known ligand 0.67

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 13/20 0.67
HDAC2 Q92769 11/20 0.67
HDAC3 O15379 3/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2108411 0.95 HDAC1 (0.74) HDAC1HDAC2HDAC3
SCHEMBL1689215 0.91 HDAC2 (0.75) HDAC1HDAC2HDAC3
SCHEMBL1689169 0.89 HDAC1 (0.64) HDAC1HDAC2HDAC3
SCHEMBL1689248 0.87 HDAC1 (0.70) HDAC1HDAC2HDAC3
SCHEMBL1689210 0.86 HDAC1 (0.90) HDAC1HDAC2HDAC3
SCHEMBL1689203 0.85 HDAC1 (0.60) HDAC1HDAC2HDAC3
SCHEMBL1689223 0.85 HDAC1 (0.71) HDAC1HDAC2HDAC3
SCHEMBL2108793 0.84 HDAC2 (0.65) HDAC1HDAC2HDAC3
SCHEMBL1689148 0.84 HDAC1 (0.59) HDAC1HDAC2HDAC3
SCHEMBL1689389 0.83 HDAC1 (0.67) HDAC1HDAC2HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1896395-B1 MODIFIED MALONATE DERIVATIVES MERCK SHARP & DOHME (US) 2015-07-15 EP claimed
US-8158825-B2 Modified malonate derivatives MERCK SHARP & DOHME CORP. (US) 2012-04-17 US claimed
US-20100160327-A1 Modified Malonate Derivatives MERCK SHARP & DOHME LLC 2010-06-24 US claimed
EP-1896395-A2 MODIFIED MALONATE DERIVATIVES Merck & Co., Inc. (US) 2008-03-12 EP claimed
WO-2007002248-A2 MODIFIED MALONATE DERIVATIVES MERCK & CO., INC. (US) 2007-01-04 WO claimed
EP-1896395-B1 MODIFIED MALONATE DERIVATIVES MERCK SHARP & DOHME (US) 2015-07-15 EP disclosed
US-8158825-B2 Modified malonate derivatives MERCK SHARP & DOHME CORP. (US) 2012-04-17 US disclosed
US-20100160327-A1 Modified Malonate Derivatives MERCK SHARP & DOHME LLC 2010-06-24 US disclosed
EP-1896395-A2 MODIFIED MALONATE DERIVATIVES Merck & Co., Inc. (US) 2008-03-12 EP disclosed
WO-2007002248-A2 MODIFIED MALONATE DERIVATIVES MERCK & CO., INC. (US) 2007-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160327-A1 Modified Malonate Derivatives ME2, ME3, ME1 HDAC1 6/4885HDAC2 42/4885HDAC3 17/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.